European Pharmaceutical Review

AUGUST 26, 2022

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. ” But why sue now? .” ” But why sue now?

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

FEBRUARY 11, 2021

Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . The vaccine stimulated antibodies against the protein in all 32 patients with early-stage AD in the study at levels that AC Immune thinks should have a therapeutic effect.

Immunization 128

Immunization Vaccines FDA 128

Pharmaceutical Technology

AUGUST 28, 2022

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, is said to have infringed patents filed by Moderna between 2010 and 2016 for its mRNA technology. This technology was vital for developing Spikevax, an mRNA Covid-19 vaccine of Moderna. 5 Omicron-targeting bivalent booster vaccine for Covid-19, mRNA-1273.222.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

JUNE 29, 2022

As the healthcare sector grows, there is a clear trend towards the expansion of biologic therapeutic drugs and vaccines like the one developed by Novavax. To summarise, bioproduction hurdles include the necessity to be fast, agile and, not to be understated, able to deliver safe and effective vaccines worldwide. _4W2cWlEb439CWlu?startTime=1632749714000

Vaccines 98

Vaccines Documentation 98

Pharmaceutical Technology

SEPTEMBER 29, 2022

The mRNA-1273.222 vaccine comprises 25µg doses of mRNA-1273 (Spikevax) and a vaccine candidate against the BA.4/BA.5 Moderna has so far obtained authorisations for Omicron-targeting bivalent booster vaccine in the US, Canada, Europe, Australia, South Korea, Switzerland, Japan, Singapore, Taiwan and the UK.

Vaccines 59

Vaccines 59

pharmaphorum

JUNE 6, 2022

With vaccine hesitancy leading to a rise in measles cases, the FDA’s approval of GlaxoSmithKline’s venerable vaccine Priorix for sale in the US looks timely. The post FDA clears GSK’s Priorix, first new MMR vaccine in 50 years appeared first on. Photo credit: CDC/Dr Heinz F Eichenwald via Wikipedia.

Vaccines 59

Vaccines FDA 59

pharmaphorum

AUGUST 16, 2022

One of the unexpected consequences of the COVID-19 vaccine race was that some top-tier vaccine companies like Merck, GSK and Sanofi ended up trailing the field, as their efforts to bring shots based on conventional technologies to patients were outstripped and outclassed by mRNA competitors from Pfizer/BioNTech and Moderna.

Vaccines 98

Vaccines Packaging 98

pharmaphorum

JULY 30, 2021

Takeda has decided development of its norovirus vaccine candidate outside Japan will be more efficient if it is spun out into a dedicated company. In 2016, the drugmaker spun out a 25-strong team of UK researchers – focused on neurological and psychiatric disorders – into a new company called Cerevance.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

OCTOBER 30, 2023

Vaccitech’s Chief Business Officer, Graham Griffiths, discusses key learnings in drug and vaccine development , the challenges of preparing for the unknown, and how strategic collaboration is imperative to achieve faster and more equitable outcomes – if and when another pandemic strikes.

Vaccines 114

Vaccines 114

pharmaphorum

SEPTEMBER 22, 2021

Texas-based Abexxa has been on the Boehringer’s radar since it was set up, as it provided seed funding for the preclinical-stage company in 2016, buying into its approach of developing antibodies against targets inside cancer cells, rather than on the cell membrane. Last December, Boehringer paid €1.8

Vaccines 92

Vaccines Immunization 92

pharmaphorum

SEPTEMBER 18, 2020

All eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle in business development elsewhere, signing back-to-back deals with Vertex and Chiesi that have brought in $100 million upfront. .

Vaccines 105

Vaccines 105

pharmaphorum

MARCH 1, 2021

AstraZeneca has sold its stake in Moderna for more than $1 billion as the US biotech’s shares soared in value following its coronavirus vaccine breakthrough. Moderna was among the first companies to get a COVID-19 vaccine approved and has been selling it at a profit, even though the project was kick-started with around $1.5

Vaccines 64

Vaccines 64

pharmaphorum

SEPTEMBER 27, 2021

As the vaccines were developed and rolled out, the disparity in their take up among different sections of the community highlighted how excluded some minority communities felt from areas of healthcare. Vaccine hesitancy was the most recent and highest profile example of distrust among minority groups towards the pharmaceutical industry.

Vaccines 122

Vaccines Communication FDA 122

pharmaphorum

MAY 26, 2021

The government’s last attempt to shake up patient data-sharing – 2013’s Care.data scheme – suffered from a number of false starts and was eventually shut down in 2016. Its demise came after the Caldicott review into safeguards found issues with consent and opt-out processes.

Communication 116

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 116

pharmaphorum

JANUARY 29, 2023

Think about recent technological breakthroughs such as mRNA vaccines and the potential for mRNA-based therapeutics, or the recent ramp up in vaccine production facilities – to name just a few examples. Attracted by healthcare’s steady and rising revenues, financial investors made 55% of 2022’s acquisitions, up from 43% in 2016.

Nursing Homes 98

Nursing Homes Hospitals Vaccines 98

European Pharmaceutical Review

SEPTEMBER 22, 2023

Active anti-Abeta immunotherapies In the 2000s, the concept of active immunotherapy targeting Abeta in Alzheimer’s patients was assessed with the ELAN vaccine (AN1792), consisting of full-length aggregated Abeta 1-42 peptide mixed with the QS21 adjuvant. 8 However, as this trial was not placebo-controlled, conclusions are difficult to draw.

Immunization 97

Immunization Vaccines Communication Labelling 97

Pharmaceutical Technology

JUNE 27, 2022

As part of the symposium, Dr Graham Foster, who was appointed National Clinical Chair for the Hepatitis C Delivery Network in January 2016, shed light on hepatitis C care strategies in England. She says this could involve using family health care facilities where children also receive their vaccines.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

MARCH 1, 2023

The Covid-19 pandemic led to massive developments and scientific advances within the field of messenger ribonucleic acid (mRNA) vaccines. Pfizer /BioNTech and Moderna’s mRNA-based vaccines were the first to receive emergency use authorisation (EUA) out of all other Covid-19 vaccines under development in late 2020.

Vaccines 59

Vaccines FDA 59

European Pharmaceutical Review

DECEMBER 14, 2023

Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. Information on demographics, prescribed medications, vaccine history, health screening, diagnosed conditions, and potential confounders, such as body mass index and ethnicity, are all logged in detail in our records.

Medical Records 116

Medical Records Vaccines Hospitals 116

pharmaphorum

JUNE 22, 2022

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. Construction of the facility is expected to start later this year, said the government, with the first mRNA vaccines due to be produced there in 2025.

Vaccines 59

Vaccines 59

The Checkup by Singlecare

NOVEMBER 30, 2023

Acetaminophen may also blunt the effects of other medications that impact the immune system, including some medicines used to manage cancer diagnoses and even the immune response following vaccinations. However, studies have concluded that using acetaminophen after vaccination to treat fever or pain did not affect antibody response.

Immunization 98

Immunization Vaccines FDA Labelling 98

pharmaphorum

NOVEMBER 16, 2020

She first joined the EMA in 2002 and filled a number of senior roles at the regulator including head of inspections, head of international liaison and head of international affairs before switching to the WHO in 2016.

Vaccines 64

Vaccines Packaging FDA 64

Blog: Ask a Student Pharmacist

AUGUST 23, 2023

In : Lyophilized Biologics and Vaccines: Modality-Based Approaches. 25-42 E Shalaev , AK Soper (2016). 6b06157 E Shalaev , K Wu, S Shamblin, JF Krzyzaniak, M Descamps (2016). D Varshney, M Singh (Eds), Springer, pp. Water in a Soft Confinement: Structure of Water in Amorphous Sorbitol. J Phys Chem B, DOI: 10.1021/acs.jpcb.6b06157

Dosage 52

Dosage Vaccines 52

ISPE

OCTOBER 25, 2022

Throughout her early career, she successfully led multiple biotech, vaccine, and API processes from late-stage research and development to clinical and commercial manufacturing. The project won an ISPE Facility of the Year Award (FOYA) for Process Innovation and was the overall FOYA winner for 2016.

Vaccines 98

Vaccines 98

pharmaphorum

JANUARY 9, 2023

1 Kenya, for example, entered the pandemic with no human vaccines manufacturing facility and established the BioVax institute for local vaccine manufacture with a major plant investment starting in 2023. Research and development spend by major companies has increased 44% since 2016.

Vaccines 98

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 98

pharmaphorum

APRIL 11, 2022

Medicines and vaccines are among the most powerful interventions that can help improve quality of life for people across the world. At Janssen, we strive to improve access to our innovative medicines and vaccines and achieve the best possible outcomes for patients across the world.

Pharmaceutical Companies 115

Pharmaceutical Companies Pharmaceutical Companies Vaccines Packaging 115

pharmaphorum

SEPTEMBER 18, 2020

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 This resulted in AstraZeneca becoming possibly the most talked-about pharma company in the world when its own vaccine emerged as the frontrunning candidate. Pfizer makes its move.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 116

Pharmaceutical Technology

SEPTEMBER 5, 2022

Following AstraZeneca’s success in vaccine development during the Covid-19 pandemic , the pharmaceutical giant is now looking to expand its scope through acquisitions across a range of indications, says CEO Pascal Soriot. “We Between 1 May 2016 and 31 May 2021, the FDA approved 207 drugs for cancer and malignant haematology.

FDA 114

FDA Vaccines 114

The Checkup by Singlecare

MAY 16, 2024

You should not get live vaccines during treatment with Remicade, and other vaccines may be less effective. Inflectra Approved by the FDA in 2016, Inflectra (infliximab-dyyb) was the first biosimilar to Remicade. There’s also a risk of cancer, like lymphoma, in children.

FDA 98

FDA Immunization Labelling Vaccines 98

Pharma Marketing Network

MARCH 2, 2022

.” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. IQVIA’s Report Highlights.

Vaccines 52

Vaccines 52

pharmaphorum

APRIL 21, 2022

Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Prescription drug use in the US soared last year, as might be expected during a pandemic, but is expected to fall back sharply in 2023, according to IQVIA’s latest report on the sector.

Vaccines 52

Vaccines 52

Pharma Marketing Network

MARCH 2, 2022

.” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. IQVIA’s Report Highlights.

Vaccines 52

Vaccines 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Immunization 98

Immunization Vaccines 98

Roots Analysis

FEBRUARY 26, 2024

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development.

Medication Delivery 52

Medication Delivery Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

pharmaphorum

FEBRUARY 23, 2022

The global health crisis caused spending on healthcare to increase , due to the funding provided to the development and purchases of vaccines and treatments, as well as support provided for the associated infrastructure. billion in 2020.

Vaccines 98

Vaccines FDA 98